Interventional technology developer AngioDynamics reported growth in revenues for the company's third fiscal quarter (end-February 29), although the company's net loss grew as well.
For the period, AngioDynamics reported net sales of $69.8 million, up 6.5% compared with the same period the year before, when the company had revenues of $65.5 million. The company posted a net loss from continuing operations for the most recent quarter of $5.7 million, compared with a net loss from continuing operations of $4.6 million in the third quarter of fiscal 2019.
For the nine-month period year to date, AngioDynamics reported revenues of $205.8 million, an increase of 3.2% compared with sales of $199.5 million in the corresponding quarter of 2019. The firm's net loss from continuing operations was $9.7 million, compared with a net loss from continuing operations of $13.9 million in the same period of 2019.
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
